- Home
- GILD vs MO Comparison
GILD vs MO Comparison
Compare GILD & MO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- MO
- Stock Information
- Founded
- GILD 1987
- MO 1822
- Country
- GILD United States
- MO United States
- Employees
- GILD N/A
- MO N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- MO Medicinal Chemicals and Botanical Products
- Sector
- GILD Health Care
- MO Health Care
- Exchange
- GILD Nasdaq
- MO Nasdaq
- Market Cap
- GILD 113.0B
- MO 95.4B
- IPO Year
- GILD 1992
- MO N/A
- Fundamental
- Price
- GILD $94.05
- MO $52.51
- Analyst Decision
- GILD Buy
- MO Buy
- Analyst Count
- GILD 26
- MO 6
- Target Price
- GILD $96.71
- MO $53.33
- AVG Volume (30 Days)
- GILD 7.2M
- MO 8.4M
- Earning Date
- GILD 02-11-2025
- MO 01-30-2025
- Dividend Yield
- GILD 3.28%
- MO 7.63%
- EPS Growth
- GILD N/A
- MO 20.56
- EPS
- GILD 0.10
- MO 5.91
- Revenue
- GILD $28,299,000,000.00
- MO $20,362,000,000.00
- Revenue This Year
- GILD $6.50
- MO $2.29
- Revenue Next Year
- GILD $0.36
- MO N/A
- P/E Ratio
- GILD $929.26
- MO $9.05
- Revenue Growth
- GILD 3.31
- MO N/A
- 52 Week Low
- GILD $62.07
- MO $39.25
- 52 Week High
- GILD $98.90
- MO $58.04
- Technical
- Relative Strength Index (RSI)
- GILD 57.65
- MO 35.00
- Support Level
- GILD $90.27
- MO $52.85
- Resistance Level
- GILD $94.05
- MO $53.88
- Average True Range (ATR)
- GILD 1.99
- MO 0.88
- MACD
- GILD 0.07
- MO -0.40
- Stochastic Oscillator
- GILD 82.30
- MO 12.14
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About MO Altria Group Inc.
Altria comprises Philip Morris USA, US Smokeless Tobacco, John Middleton, Horizon Innovations, and Helix Innovations. Through its tobacco subsidiaries, Altria maintains the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the US with 42% annual share in 2023. Beyond its core business, it holds an 8% interest in the world's largest brewer, Anheuser-Busch InBev, a 42% stake in cannabis manufacturer Cronos, acquired Njoy Holdings in 2023, and operates a joint venture with Japan Tobacco in the heated tobacco category. It also recently disposed of its investment in Juul Labs.